What is the mechanism of action of sulfasalazine?

Mechanism of Action of Sulfasalazine

Sulfasalazine functions as a prodrug that is cleaved by colonic bacteria into 5-aminosalicylic acid (5-ASA) and sulfapyridine, with the 5-ASA moiety providing the primary therapeutic anti-inflammatory effects through multiple mechanisms including activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ), reactive oxygen scavenging, adenosine release, and inhibition of pro-inflammatory mediators. 1, 2

Prodrug Activation and Metabolism

• Sulfasalazine consists of 5-ASA linked to sulfapyridine via an azo bond 3
• Colonic bacteria cleave this azo bond, releasing the two moieties in the colon 3, 1
• The 5-ASA component is the therapeutically active compound for treating ulcerative colitis, while sulfapyridine causes most adverse effects 3
• Less than 15% of oral sulfasalazine is absorbed as parent drug, with most reaching the colon intact for bacterial metabolism 1

Primary Anti-Inflammatory Mechanisms

PPAR-γ Activation (Most Recent Mechanistic Understanding)

• 5-ASA activates peroxisome proliferator-activated receptor-gamma (PPAR-γ), nuclear receptors that control inflammation, cell proliferation, apoptosis, and metabolic function 2
• PPAR-γ receptors are expressed at particularly high levels in colon epithelial cells 2
• 5-ASA displaces other PPAR-γ ligands (like rosiglitazone and GW1929) from their binding sites at concentrations corresponding to luminal levels in ulcerative colitis patients taking oral mesalazine 2
• In genetically engineered PPAR-γ+/- knockout mice, 5-ASA becomes ineffective, confirming this mechanism is essential for its anti-inflammatory action 2

Reactive Oxygen Species Scavenging

• Sulfasalazine and 5-ASA function as reactive oxygen scavengers, blocking bile acid-induced and xanthine-xanthine oxidase-induced epithelial cell loss 4
• Both compounds suppress reactive oxygen formation by colonic mucosal scrapings and isolated crypt epithelium 4
• This scavenging activity blocks subsequent increases in epithelial proliferative activity and ornithine decarboxylase activity 4

Adenosine-Mediated Anti-Inflammatory Effects

• Sulfasalazine inhibits AICAR (5-aminoimidazole-4-carboxamidoribonucleotide) transformylase, an enzyme in de novo purine biosynthesis, leading to intracellular AICAR accumulation 5
• This accumulation promotes adenosine release at inflamed sites (increasing exudate adenosine concentration from 127 nM to 869 nM in animal models) 5
• Released adenosine diminishes inflammation via occupancy of A2 receptors on inflammatory cells 5
• Adenosine deaminase or A2 receptor antagonists completely reverse sulfasalazine's anti-inflammatory effects, confirming this mechanism 5

Inhibition of Pro-Inflammatory Mediators

• Sulfasalazine markedly inhibits extracellular release of secretory phospholipase A2 (sPLA2), a proinflammatory enzyme 6
• The effect is evident at 50 μM and maximal at 400 μM, acting on post-transcriptional release rather than synthesis 6
• Sulfasalazine inhibits TNF-α expression in macrophages by inducing apoptosis through caspase 8 activation 7
• The drug inhibits formation of leukotrienes and possibly second messenger compounds at the phospholipase C level 6

Clinical Context for Different Conditions

Ulcerative Colitis

• In ulcerative colitis, the major therapeutic action resides in the 5-ASA moiety delivered to the colon 1
• The mechanism involves local anti-inflammatory effects through PPAR-γ activation and reactive oxygen scavenging in colonic epithelium 2, 4
• 4 grams of sulfasalazine provides approximately 1.6 grams of 5-ASA 3

Rheumatoid Arthritis and Ankylosing Spondylitis

• For peripheral arthritis in inflammatory arthropathies, sulfasalazine's mechanism involves systemic anti-inflammatory effects through adenosine release and inhibition of sPLA2 3, 5
• The drug has little benefit for axial skeleton symptoms in ankylosing spondylitis, suggesting its mechanism is more effective for peripheral inflammation 3
• Sulfasalazine should be considered primarily for patients with prominent peripheral arthritis 3

Important Mechanistic Distinctions

• Sulfapyridine (the other cleavage product) is therapeutically inactive and causes most adverse effects 3, 4
• The split products have different actions: 5-aminosalicylic acid (400 μM) and sulfapyridine (400 μM) alone had no impact on sPLA2 release, demonstrating the intact molecule or specific metabolite is required for certain effects 6
• The anti-inflammatory mechanisms are multi-factorial and operate through different pathways depending on the tissue and inflammatory context 1, 2, 5